ABCG2 and Cognitive impairment: Studies could also be performed in mouse models of AD to determine if increasing the expression of Aβ-regulating ABC transporters would further slow the progression of AD-related neuropathology or cognitive deficits when combined with administration of Lecanemab or Donanemab; if encouraging findings are obtained, this could be examined further in an AD pilot study.